
Hitachi Ltd
Hitachi Ltd
12 Projects, page 1 of 3
assignment_turned_in Project2021 - 2025Partners:University of Strathclyde, Bae Systems Defence Ltd, EURATOM/CCFE, Hitachi Ltd, BAE Systems Maritime +6 partnersUniversity of Strathclyde,Bae Systems Defence Ltd,EURATOM/CCFE,Hitachi Ltd,BAE Systems Maritime,University of Strathclyde,BAE Systems Maritime,Sellafield Ltd,CCFE/UKAEA,Hitachi Ltd,Sellafield LtdFunder: UK Research and Innovation Project Code: EP/V051814/1Funder Contribution: 1,072,240 GBPMany current challenges in Non-Destructive Evaluation (NDE) stem from the increased use of advanced materials and manufacturing processes that push the limits of materials' performance. NDE techniques are required that can cope with extreme environments (high temperature / radioactive environments), restricted access (inside engines or though access ports), and complex geometries. To address these challenges, this project will develop a new capability for real-time, remote ultrasonic imaging that can be used for NDE. This engineering challenge will be achieved by introducing a conceptual change to phased array ultrasonics, beyond the limits of geometrical, ultrasonic frequency and mode array characteristics, by adapting the array to the demands of the inspected structure, on-the-fly, and thus transforming the field. The long-term vision behind this project goes beyond inspection, to develop a method for monitoring and control of in-process parameters, in places of extreme environments such as fusion reactors or turbine engines. The industrial importance of the project is demonstrated by the significant cash and in-kind contributions of the project partners.
more_vert assignment_turned_in Project2019 - 2027Partners:Oak Ridge National Laboratory, Sellafield Ltd, Cavendish Nuclear, Westinghouse Electric (Sweden), AWE +55 partnersOak Ridge National Laboratory,Sellafield Ltd,Cavendish Nuclear,Westinghouse Electric (Sweden),AWE,Nuclear Decommissioning Authority,EDF Energy Plc (UK),Hitachi Europe Ltd,Westinghouse Electric (United States),Thor Energy AS,Horizon Nuclear Power Services Ltd,Wood Group,DBD ltd,Sellafield Ltd,Rolls-Royce (United Kingdom),EDF Energy (United Kingdom),Laing O'Rourke plc,DBD ltd,ORNL,Khalifa University,British Energy Generation Ltd,Atkins Ltd,Thor Energy AS,University Of New South Wales,Hitachi-GE Nuclear Energy Ltd,Henry Royce Institute,Atkins (United Kingdom),AWE plc,Australian Nuclear Science and Tech,Atkins Ltd,Wood Group,Tokamak Solutions UK Ltd,ANSTO,UKAEA,National Nuclear Laboratory (NNL),FRAZER-NASH CONSULTANCY LTD,Framatome ANP,Tokamak Energy Ltd,TOKAMAK ENERGY LTD,Cavendish Nuclear,NNL,Hitachi Ltd,UNSW,Khalifa University,Laing O'Rourke,Hitachi-GE Nuclear Energy Ltd,Frazer-Nash Consultancy Ltd,University New South Wales at ADFA,Westinghouse Electric Sweden AB,Radioactive Waste Management Ltd.,United Kingdom Atomic Energy Authority,Rolls-Royce Plc (UK),Radioactive Waste Management Ltd.,ANSTO,Framatone ANP,Imperial College London,Rolls-Royce (United Kingdom),Henry Royce Institute,Horizon Nuclear Power Services Ltd,EURATOM/CCFEFunder: UK Research and Innovation Project Code: EP/S023844/1Funder Contribution: 6,596,590 GBPThe EPSRC Centre for Doctoral Training (CDT) in Nuclear Energy Futures aims to train a new generation of international leaders, at PhD level, in nuclear energy technology. It is made up of Imperial College London (lead), Bristol University, Cambridge University, Open University and Bangor University. These institutions are some of the UK's leading institutions for research and teaching in nuclear power. The CDTs key focus is around nuclear fission i.e. that is the method of producing energy by splitting the atom, which currently accounts for 11% of the world's electricity and 20% of the UK's electricity, whilst producing very low levels of carbon emissions (at levels the same as renewable energy, such as wind). The CDT whilst focused on fission energy technologies will also have PhD projects related to fusion nuclear energy and projects needed or related to nuclear energy such as seismic studies, robotics, data analytics, environmental studies, policy and law. The CDT's major focus is related to the New Nuclear Build activities at Hinkley Point, Somerset and the Anglesey site in north Wales, where EDF Energy and Horizon, respectively, are building new fission power plants that will produce around 3.2 and 2.7 GWe of nuclear power (about 13% of the UK current electricity demand). The CDT will provide the skills needed for research related to these plants and potential future industry leaders, for nuclear decommissioning of current plants (due to come off-line in the next decade) and to lead the UK in new and innovative technologies for nuclear waste disposal and new reactor technologies such as small modular reactors (SMRs). The need for new talented PhD level people is very high as many of the UK's current technical experts were recruited in the 1970s and 80s and many are near retirement and skills sector studies have shown many more are needed for the new build projects. The CDT will champion teaching innovation and will produce a series of bespoke courses that can be delivered via on-line media by the very best experts in the field from across the CDT covering areas such as the nuclear fuel cycle; waste and decommissioning; small modular reactors; policy, economics and regulation; thermal hydraulics and reactor physics as well as leading on responsible research and innovation in the sector. The CDT is supported by a wide range of nuclear companies and stakeholders. These include those involved in the new build process in the UK such as EDF Energy, Hitachi-GE, Horizon and Rolls-Royce, the latter of which are developing a UK advanced modular reactor design. International nuclear stakeholders from countries such as the USA, UAE, Australia and France will support the student development and the CDT programme. The students in the CDT will cover a very broad training in all aspects of nuclear power and importantly for this sector will engage in both media training activities and public outreach to make nuclear power more open to the public, government and scientists and engineers outside of the discipline.
more_vert assignment_turned_in Project2014 - 2023Partners:Samsung Advanced Institute of Technology, Moorfields Eye NHS Foundation Trust, Fujifilm Visualsonics Inc, icometrix, The Francis Crick Institute +114 partnersSamsung Advanced Institute of Technology,Moorfields Eye NHS Foundation Trust,Fujifilm Visualsonics Inc,icometrix,The Francis Crick Institute,Elekta UK Ltd,University College Hospital,Microsoft Research,Renishaw plc (UK),Dexela Ltd,Agility Design Solutions,Moorfields Eye Hosp NHS Foundation Trust,Philips Healthcare,Millennium the Takeda Oncology Company,IXICO Technologies Ltd,Beijing Normal University,Philips Healthcare (Global),Alzheimer's Society,Siemens,Hamamatsu Photonics UK Ltd,Vision RT Ltd,Netherlands Cancer Institute,Diameter Ltd,Pelican Cancer Foundation,ESI Group,INRA Sophia Antipolis,Vision RT Ltd,Medtronic,Netherlands Cancer Institute,Bruker UK Ltd,UCL,Agency for Science Technology-A Star,Blackford Analysis Ltd,Mediso,Danish Research Centre for Magnetic Reso,Medtronic (United States),Brain Products GmbH,CANCER RESEARCH UK,Samsung Advanced Institute of Technology,Olea Medical,Elekta UK Ltd,Rigaku,RAPID Biomedical GmbH,Cancer Research UK,Hvidovre Hospital,University College London Hospital (UCLH) NHS Foundation Trust,RENISHAW,Yale University,Agilent Technologies UK Ltd,Siemens AG,Lightpoint Medical Ltd,Great Ormond Street Hospital Children's Charity,Precision Acoustics Ltd,Lightpoint Medical Ltd,Hitachi Ltd,Yale University,Beijing Normal University,Agilent Technologies (United Kingdom),Imperial Cancer Research Fund,MR Solutions Limited,Pelican Cancer Foundation,Imaging Equipment Limited,Alzheimer's Research UK,Agency for Science Technology (A Star),Child Health Research Appeal Trust,Fujifilm Visualsonics Inc,TeraView Limited,University of Pennsylvania,The Huntington's Disease Association,Agilent Technologies (United States),Microsoft Research,Creatv MicroTech (United States),Rigaku,University College London Hospitals,PerkinElmer (United Kingdom),GE Aviation,GE Healthcare,The Huntington's Disease Association,Bruker UK Ltd,PULSETEQ LTD,Philips (Netherlands),Olea Medical,MR Solutions Limited,Teraview Ltd,Pulseteq Ltd,Dexela Ltd,Millennium the Takeda Oncology Company,Siemens AG,Danish Research Centre for Magnetic Reso,WF,Teraview Ltd,Blackford Analysis Ltd,Medtronic,Imaging Equipment Ltd,Hitachi Ltd,JPK Instruments Limited,Alzheimer's Research UK,Mirada Solutions,The Francis Crick Institute,Wolfson Foundation,Precision Acoustics (United Kingdom),IXICO Ltd,Child Health Research Appeal Trust,Siemens AG (International),UU,Brain Products GmbH,Hamamatsu Photonics UK Ltd,University of Pennsylvania,Great Ormond Street Hospital,MRC National Inst for Medical Research,RAPID Biomedical GmbH,ESI Group,University of Utah,GE Healthcare,Mirada Solutions,icoMetrix,Alzheimer's Society,Mediso,Creatv MicroTechFunder: UK Research and Innovation Project Code: EP/L016478/1Funder Contribution: 5,797,790 GBPMedical imaging has transformed clinical medicine in the last 40 years. Diagnostic imaging provides the means to probe the structure and function of the human body without having to cut open the body to see disease or injury. Imaging is sensitive to changes associated with the early stages of cancer allowing detection of disease at a sufficient early stage to have a major impact on long-term survival. Combining imaging with therapy delivery and surgery enables 3D imaging to be used for guidance, i.e. minimising harm to surrounding tissue and increasing the likelihood of a successful outcome. The UK has consistently been at the forefront of many of these developments. Despite these advances we still do not know the most basic mechanisms and aetiology of many of the most disabling and dangerous diseases. Cancer survival remains stubbornly low for many of the most common cancers such as lung, head and neck, liver, pancreas. Some of the most distressing neurological disorders such as the dementias, multiple sclerosis, epilepsy and some of the more common brain cancers, still have woefully poor long term cure rates. Imaging is the primary means of diagnosis and for studying disease progression and response to treatment. To fully achieve its potential imaging needs to be coupled with computational modelling of biological function and its relationship to tissue structure at multiple scales. The advent of powerful computing has opened up exciting opportunities to better understand disease initiation and progression and to guide and assess the effectiveness of therapies. Meanwhile novel imaging methods, such as photoacoustics, and combinations of technologies such as simultaneous PET and MRI, have created entirely new ways of looking at healthy function and disturbances to normal function associated with early and late disease progression. It is becoming increasingly clear that a multi-parameter, multi-scale and multi-sensor approach combining advanced sensor design with advanced computational methods in image formation and biological systems modelling is the way forward. The EPSRC Centre for Doctoral Training in Medical Imaging will provide comprehensive and integrative doctoral training in imaging sciences and methods. The programme has a strong focus on new image acquisition technologies, novel data analysis methods and integration with computational modelling. This will be a 4-year PhD programme designed to prepare students for successful careers in academia, industry and the healthcare sector. It comprises an MRes year in which the student will gain core competencies in this rapidly developing field, plus the skills to innovate both with imaging devices and with computational methods. During the PhD (years 2 to 4) the student will undertake an in-depth study of an aspect of medical imaging and its application to healthcare and will seek innovative solutions to challenging problems. Most projects will be strongly multi-disciplinary with a principle supervisor being a computer scientist, physicist, mathematician or engineer, a second supervisor from a clinical or life science background, and an industrial supervisor when required. Each project will lie in the EPSRC's remit. The Centre will comprise 72 students at its peak after 4 years and will be obtaining dedicated space and facilities. The participating departments are strongly supportive of this initiative and will encourage new academic appointees to actively participate in its delivery. The Centre will fill a significant skills gap that has been identified and our graduates will have a major impact in academic research in his area, industrial developments including attracting inward investment and driving forward start-ups, and in advocacy of this important and expanding area of medical engineering.
more_vert assignment_turned_in Project2019 - 2028Partners:Allergan Limited (UK), Knowledge Transfer Network Ltd, Knowledge Transfer Network, Pfizer, Elanco Animal Health (UK) +70 partnersAllergan Limited (UK),Knowledge Transfer Network Ltd,Knowledge Transfer Network,Pfizer,Elanco Animal Health (UK),Eli Lilly S.A. - Irish Branch,Allergan Limited (UK),GSK,Hitachi Ltd,Vironova,Albumedix Ltd,Synthace Limited,Prokarium Ltd,Centre for Process Innovation (Dup'e),Tillingbourne Consulting Limited,Applikon Biotechnology Limited,Aglaris Ltd.,Catapult Cell Therapy,Aglaris Ltd.,Britest Limited,GE Aviation,MEDISIEVE,Hitachi Chemical Co. Ltd,Puridify LTD,Pall Corporation (UK),Puridify LTD,Centre for Process Innovation,Darlington,Pall Corporation (United Kingdom),deltaDOT Ltd,GlaxoSmithKline (Harlow),Monaghan Biosciences (Ireland),BPL,Albumedix Ltd,Allergan (Ireland),Tillingbourne Consulting Limited,Pfizer,Cell Therapy Catapult (replace),LGC,LGC Ltd,Biovault Technical Ltd.,Prokarium Ltd,Janssen (Ireland),Elanco Animal Health (UK),Cobra Biologics,Medicines Manufacturing Ind Partnership,BPL BioProducts Laboratory,Recipharm Cobra Biologics,3M (United Kingdom),3M United Kingdom Plc,UCB Pharma (United Kingdom),UCL,GlaxoSmithKline PLC,Oxford BioMedica (UK) Ltd,Vironova,Hitachi Chemical Co. Ltd,MedImmune Ltd,CPI Ltd,Eli Lilly (Ireland),BRITEST Ltd,Axitan Limited,Alexion Pharmaceuticals,Synthace Ltd,Alexion Pharmaceuticals,Oxford BioMedica (UK) Ltd,Axitan Limited,Applikon Biotechnology Limited,UCB UK,Process Systems Enterprises Ltd,Johnson & Johnson (United States),deltaDOT Ltd,Biovault Technical Ltd.,Eli Lilly (United States),Process Systems Enterprises Ltd,Astrazeneca,UCB Celltech (UCB Pharma S.A.) UKFunder: UK Research and Innovation Project Code: EP/S021868/1Funder Contribution: 6,156,440 GBPThe UK government's support for the Life Sciences Industry Strategy (Bell Report, 2017) recognises the importance of developing new medicines to facilitate UK economic growth. Examples include new antibody therapies for the treatment of cancer, new vaccines to control the spread of infectious diseases and the emergence of cell and gene therapies to cure previously untreatable conditions such as blindness and dementia. Bioprocessing skills underpin the safe, cost-effective and environmentally friendly manufacture of this next generation of complex biological products. They facilitate the rapid translation of life science discoveries into the new medicines that will benefit the patients that need them. Recent reports, however, highlight specific skills shortages that constrain the UK's capacity to capitalise on opportunities for wealth and job creation in these areas. They emphasise the need for 'more individuals trained in advanced manufacturing' and for individuals with bioprocessing skills who can address the 'challenges with scaling-up production using biological materials'. The UCL EPSRC CDT in Bioprocess Engineering Leadership has a successful track record of equipping graduate scientists and engineers with the bioprocessing skills needed by industry. It will deliver a 'whole bioprocess' training theme based around the core fermentation and downstream processing skills underpinning medicines manufacture. The programme is designed to accelerate graduates into doctoral research and to build a multidisciplinary research cohort; this will be enhanced through a partnership with the Synthesis and Solid State Pharmaceutical Centre (SSPC) and the National Institute for Bioprocess Research and Training (NIBRT) in Ireland. Research projects will be carried out in partnership with leading UK and international companies. The continued need for the CDT is evidenced by the fact that 96% of previous graduates have progressed to relevant bioindustry careers and many are now in senior leadership positions. The next generation of molecular or cellular medicines will be increasingly complex and hence difficult to characterise. This means they will be considerably more difficult to manufacture at large scale making it harder to ensure they are not only safe but also cost-effective. This proposal will enable the CDT to train future bioindustry leaders who possess the theoretical knowledge and practical and commercial skills necessary to manufacture this next generation of complex biological medicines. This will be achieved by aligning each researcher with internationally leading research teams and developing individual training and career development programmes. In this way the CDT will contribute to the future success of the UK's bioprocess-using industries.
more_vert assignment_turned_in Project2014 - 2023Partners:UCL, Hamamatsu Photonics UK Ltd, Hitachi Cambridge Laboratory, Photon Design Ltd, CIP Technologies +81 partnersUCL,Hamamatsu Photonics UK Ltd,Hitachi Cambridge Laboratory,Photon Design Ltd,CIP Technologies,BAE Systems (UK),UKRI,Xilinx Corp,Swimovate Ltd,Thales UK Ltd,X-FAB,Innovate UK,Qioptiq Ltd,Hitachi Cambridge Laboratory,CERN,Columbia University,Zinwave Ltd,Modern Built Environment,UK Innovation Forum Limited,SWISSto12 SA,Hitachi Ltd,Silixa Ltd,CAS,Polatis Ltd,X-FAB,Huber+Suhner (UK) Ltd,Columbia University,Avago Technologies,Inphi Ltd UK,Teraview Ltd,Selex ES Ltd,Swimovate Ltd,Oclaro Technology UK,University of Cambridge,Oclaro Technology UK,Xyratex Technology Limited,Selex-ES Ltd,Dow Chemical Company,Inphi Ltd UK,Xtera Communications Limited,Fraunhofer UK Research Ltd,TREL,Precision Acoustics Ltd,Moor Instruments (United Kingdom),Fraunhofer UK Research Ltd,Moor Instruments Ltd,SWISSto12 SA,Teraview Ltd,PervasID Ltd,XYRATEX,Xtera Communications Limited,PervasID Ltd,Technology Strategy Board (Innovate UK),Bae Systems Defence Ltd,Silixa Ltd,Defence Science & Tech Lab DSTL,Hitachi Ltd,THALES UK,TeraView Limited,Toshiba Research Europe Ltd,CERN,Chinese Academy of Sciences,SELEX Sensors & Airborne Systems Ltd,BAE Systems (Sweden),Precision Acoustics (United Kingdom),Xilinx Corp,PHOTON DESIGN LIMITED,LOCKHEED MARTIN ACULIGHT CORPORATION,Cambridge Integrated Knowledge Centre,Hamamatsu Photonics UK Ltd,DSTL,Chinese Academy of Science,Columbia University,Qioptiq Limited,Defence Science & Tech Lab DSTL,Thales Aerospace,COSTAIN LTD,Broadcom (United Kingdom),Dow Corning Corporation,UNIVERSITY OF CAMBRIDGE,BAE Systems (United Kingdom),CIP Technologies,Costain Ltd,Zinwave,UK Innovation Forum Limited,Dow Corning Corporation (International)Funder: UK Research and Innovation Project Code: EP/L015455/1Funder Contribution: 4,361,750 GBPThis proposal seeks funding to create a Centre for Doctoral Training (CDT) in Integrated Photonic and Electronic Systems. Photonics plays an increasing role in systems, ranging from sensing, biophotonics and manufacturing, through communications from the chip-to-chip to transcontinental scale, to the plethora of new screen and projection display technologies that have been developed, bringing higher resolution, lower power operation and enabling new ways of human-machine interaction. These advances have set the scene for a major change in commercialisation activity where photonics and electronics will converge in a wide range of information, sensing, communications, manufacturing and personal healthcare systems. Currently, systems are realised by combining separately developed photonic components, such as lasers and photodetectors with electronic circuits. This approach is labour intensive and requires many electrical interconnects as well as optical alignment on the micron scale. Devices are optimised separately and then brought together to meet systems specifications. Such an approach, although it has delivered remarkable results, not least the communications systems upon which the internet depends, limits the benefits that could come from the full integration of photonics with electronics and systems. To achieve such integration requires researchers who have not only deep understanding of their specialist area, but also an excellent understanding across the fields of electronic and photonic hardware and software. This proposal therefore seeks to meet this important need, building upon the uniqueness and extent of the UCL and Cambridge research, where research activities are already focussing on the direct monolithic integration of lasers with silicon electronics, new types of displays based on polymer and holographic projection technology, the application of photonic communications to computing, personal information systems and indeed consumer products (via board-to-board, chip to chip and later on-chip interconnects), the increased use of photonics in industrial processing and manufacture, techniques for the low-cost roll-out of optical fibre to replace the copper network, the substitution of many conventional lighting products with photonic light sources and extensive application of photonics in medical diagnostics and personalised medicine. Many of these activities will increasingly rely on more advanced electronic systems integration, and so the proposed CDT includes experts in electronic circuits, computer systems and software. By drawing these complementary activities together, and building upon initial work towards this goal carried out within our previously funded CDT in Photonic Systems Development, it is proposed to develop an advanced training programme to equip the next generation of very high calibre doctoral students with the required technical expertise, commercial and business skills, and thus provide innovation opportunities for the integration of photonic and electronics in new systems in the coming years. It should be stressed that the CDT will provide a wide range of methods for learning for research students, well beyond that conventionally available, so that they can gain the required skills. In addition to conventional lectures and seminars, for example, there will be bespoke experimental coursework activities, reading clubs, roadmapping activities, secondments to companies and other research laboratories and business planning courses. The integration of photonic and electronic systems is likely to widen the range of systems into which these technologies are deployed in other key sectors of the economy, such as printing, consumer electronics, computing, defence, energy, engineering, security and medicine. As a result, a key feature of the CDT will be a developed awareness in its student cohorts of the breadth of opportunity available and a confidence that they can make impact therein.
more_vert
chevron_left - 1
- 2
- 3
chevron_right